CD20 antibody primes B lymphocytes for type I interferon production.
about
Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
P2860
CD20 antibody primes B lymphocytes for type I interferon production.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
CD20 antibody primes B lymphocytes for type I interferon production.
@ast
CD20 antibody primes B lymphocytes for type I interferon production.
@en
CD20 antibody primes B lymphocytes for type I interferon production.
@nl
type
label
CD20 antibody primes B lymphocytes for type I interferon production.
@ast
CD20 antibody primes B lymphocytes for type I interferon production.
@en
CD20 antibody primes B lymphocytes for type I interferon production.
@nl
prefLabel
CD20 antibody primes B lymphocytes for type I interferon production.
@ast
CD20 antibody primes B lymphocytes for type I interferon production.
@en
CD20 antibody primes B lymphocytes for type I interferon production.
@nl
P2093
P2860
P1433
P1476
CD20 antibody primes B lymphocytes for type I interferon production.
@en
P2093
Andrew Staedman
Dongsheng Xu
Luwen Zhang
P2860
P304
P356
10.1371/JOURNAL.PONE.0067900
P407
P577
2013-06-18T00:00:00Z